To include your compound in the COVID-19 Resource Center, submit it here.

Zontivity vorapaxar: Additional Phase III data

Additional data from 3,623 patients with diabetes mellitus and a prior MI and without a history of stroke or transient ischemic attack in the double-blind Phase III TRA 2P-TIMI 50 trial showed that Zontivity vorapaxar plus standard of care (SOC)

Read the full 404 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE